Navigation Links
Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial,Results at EuroPCR 2007

BARCELONA, Spain, May 22, 2007 /PRNewswire/ -- Principal investigators for the COSTAR II (CObalt Chromium STent with Antiproliferative for Restenosis) trial, the pivotal study for the CoStar(R) cobalt chromium paclitaxel-eluting coronary stent, presented today the clinical trial results of the study at EuroPCR 2007. The investigators confirmed that the study failed to meet its primary endpoint. Conor previously announced this conclusion in a press release on Monday, May 7, 2007.

The COSTAR II trial compared the CoStar(R) stent with the Taxus Express(2) paclitaxel drug-eluting stent, and was designed to demonstrate non-inferiority at eight-month follow-up with respect to major adverse cardiac events (MACE) in patients with multi-vessel or single-vessel disease. In this trial, MACE was defined as a composite of clinically driven target vessel revascularization (re-treatment), new myocardial infarction (heart attack or MI) related to the target vessel and cardiac death related to an intervened vessel.

At eight-month follow-up, the CoStar(R) stent had significantly higher MACE rate than the Taxus stent (11.0 percent vs. 6.9 percent; p=0.005). This difference was largely due to a significantly higher incidence of clinically driven target vessel revascularization (8.1 percent vs. 4.3 percent; p=0.002). No significant differences were found in terms of cardiac death (0.5 percent for the CoStar(R) stent vs. 0.7 percent for the Taxus stent; p=0.541) or new MI (3.4 percent vs. 2.4 percent; p=0.242).

The investigators also reported that the protocol-defined stent thrombosis rates at nine-month were similar between both arms of the study. The total stent thrombosis rate for the CoStar(R) stent was 0.6 percent vs. 0.1 percent for the Taxus stent (p=0.252).

"Comparably higher re-intervention rates are largely responsible for the outcome of this trial," said Mitchell W. Krucoff, M.D., from Duke Cli
'"/>




Page: 1 2 3

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:12/24/2014)... Dec. 23, 2014  Lockton Dunning Benefits, the ... Companies, announced the addition of Vice President ... Lockton Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... industry experience to the position.  Most recently, she ... at Diplomat Specialty Pharmacy, where she has held ...
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014  Endo ... ENDP ) (TSX: ENL), and BioDelivery Sciences ... that they have submitted a New Drug Application (NDA) ... and Drug Administration (FDA).  Buprenorphine HCl Buccal Film is ... to require daily, around-the-clock, long-term opioid treatment and for ...
(Date:12/22/2014)... ALISO VIEJO, Calif. , Dec. 22, 2014 /PRNewswire/ ... moved into expanded corporate offices in Aliso ... President, announced that due to the tremendous growth and ... critically needed. Sales of patented SnoreRx, the anti snore ... administrative offices. He said, "We are now in ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... PARIS, September 13, 2010 ... ... var ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... 11 The Mobile Dog Heart Health Tour is ... of free heart health examinations in San Antonio,s McAllister ... September 17, certified veterinary cardiologists will be performing on ... well as educating owners about canine heart disease. ...
Cached Medicine Technology:Biosystems International Merges With Microbiochips 2Biosystems International Merges With Microbiochips 3Biosystems International Merges With Microbiochips 4Biosystems International Merges With Microbiochips 5Biosystems International Merges With Microbiochips 6Biosystems International Merges With Microbiochips 7Free Dog Heart Checks at McAllister Park 2Free Dog Heart Checks at McAllister Park 3
(Date:12/24/2014)... In June 2014, 15 injured veterans ... hand cycles and recumbent bicycles nearly 800 miles from ... CanAm Veterans’ Challenge . “Capital to Capital,” the new ... this inspiring ride, is now available through multiple online ... photographs taken during the two-week ride, the 92 page ...
(Date:12/24/2014)... -- Each year, more than one-third of the more ... because of extreme heat conditions, according to recent federal ... stroke is the leading cause of heat-related illness among ... urinary tract infections, also put older people at higher ... data should help health care systems anticipate and perhaps ...
(Date:12/24/2014)... (HealthDay News) -- Though most patients with obsessive-compulsive disorder ... between 10 percent to 20 percent have a form ... experts say. However, patients with this so-called "refractory ... type of brain surgery that disables certain brain networks ... distinguish between patients most likely to benefit from the ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 B. E. ... to healthcare providers, has been retained to lead a ... Tri-City Medical Center in Oceanside, Calif. The top ... B. E. Smith has recently placed more than 900 ... is a community owned, 397-bed, Gold Seal-approved, full-service acute-care ...
(Date:12/22/2014)... December 22, 2014 Fad diets ... The reason why most fad diets have hung around ... problem with fad diets is that, as the body becomes ... dieter uncertain of how to reset the metabolism to return ... Diet Doc developed their all-inclusive diet plans that ...
Breaking Medicine News(10 mins):Health News:New Commemorative Book Celebrates CanAm Veterans’ Challenge Bike Ride 2Health News:New Commemorative Book Celebrates CanAm Veterans’ Challenge Bike Ride 3Health News:Heat Stroke, Kidney Failure Help Drive Illnesses From Extreme Heat 2Health News:Scans May Spot People Who'll Benefit From Surgery for OCD 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 3Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 3Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 4
... In conjunction with HBO, Cox Communications will allow all digital ... -- to have free access to its upcoming documentary series ... access all four documentaries in the series via Cox,s On ... to the programs through June 8th. "Cox is happy to ...
... The Healthcare Group at Frost & Sullivan ... Briefing Presentation on the Pharmaceutical CRM Market to be ... GMT. (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )2008 has ushered in ... The pharmaceutical industry is adopting a cautious approach, delaying ...
... epitomizes the collaborative development process of software developer, PercipEnz Technologies, Inc. ... user interface but also incorporates over 200 enhancement requests provided by ... ... 27, 2009 -- The latest version of the OnCore(r) clinical ...
... Inc. (ARI) announced today it has launched Phase 2 of its clinical ... ... GA (PRWEB) April 24, 2009 -- Aderans Research Institute Inc. (ARI) announced ... hair regeneration for men and women. Structured around the findings of the ...
... malpractice challenge by introducing low tech solution to ... standardized shift reporting and note taking to help ... day tasks.RNReport Card is more efficient by standardizing ... fits conveniently in the pocket of your scrubs ...
... Flexibility and High-Content Screening ThroughputSUNNYVALE, CA, April ... leader in innovative solutions for drug discovery ... the Society for Biomolecular Sciences (SBS) Conference ... availability of the MetaXpressPowerCore(TM) and MetaXpress(R) 3.0 ...
Cached Medicine News:Health News:Cox Communications Offers Free Access to HBO(R) Documentary Series, The Alzheimer's Project, to All Digital Customers 2Health News:Frost & Sullivan: The Pharmaceutical Customer Relationship Management Market - What are the Emerging Trends and Opportunities? 2Health News:Frost & Sullivan: The Pharmaceutical Customer Relationship Management Market - What are the Emerging Trends and Opportunities? 3Health News:OnCore(r) 9.0 Released: 'Top 5' Priorities and Collaborative Initiatives Cornerstones of Product Development 2Health News:OnCore(r) 9.0 Released: 'Top 5' Priorities and Collaborative Initiatives Cornerstones of Product Development 3Health News:OnCore(r) 9.0 Released: 'Top 5' Priorities and Collaborative Initiatives Cornerstones of Product Development 4Health News:Aderans Research Launches Second Phase of Hair Loss Study 2Health News:RN Sisters Bring Low-Tech Innovations to New Nurses and Nursing Students 2Health News:MDS Analytical Technologies Releases MetaXpressPowerCore(TM) and MetaXpress(R) 3.0 Cellular Imaging Software 2Health News:MDS Analytical Technologies Releases MetaXpressPowerCore(TM) and MetaXpress(R) 3.0 Cellular Imaging Software 3
Rapid latex agglutination test for presumptive identification of E. coli serogroup O157:H7 isolates. Colorimetric with red O157 latex and blue H7 latex....
Direct antigen rapid immunoassay for the detection of Shiga toxin-producing E. coli 0157, which aids in the diagnosis of E. coli 0157:H7 infection...
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
Inquire...
Medicine Products: